The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics
Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.
 
Talia Golan
Honoraria - MSD; Rafael Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; MSD; Teva
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - AstraZeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Talia Shentzer Kutiel
No Relationships to Disclose
 
Maya Gottfried
No Relationships to Disclose
 
Alona Zer
Stock and Other Ownership Interests - Nixio
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Oncotest/Rhenium; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Aviad Zick
Research Funding - Karyopharm Therapeutics (Inst); Merck KGaA (Inst); Roche (Inst)
 
Ayelet Shai
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Novartis; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Larissa Ryvo
No Relationships to Disclose
 
Julia Dudnik
No Relationships to Disclose
 
Nir Peled
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer (Inst); Roche/Genentech (Inst)
 
Galia Oberkovitz
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Fan Yang
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Shmuel Sharoni
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Changting Meng
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Dayana Michel
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Eric Sbar
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Karyopharm Therapeutics; Merck; Pfizer
Research Funding - Karyopharm Therapeutics; Merck
Travel, Accommodations, Expenses - Karyopharm Therapeutics; Merck
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Michael Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
No Relationships to Disclose
 
Ravit Geva
Stock and Other Ownership Interests - BOL Pharma; Pyxis
Honoraria - Bristol-Myers Squibb; Janssen; Lilly; Medison; Merck KGaA; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; BOL Pharma; Eisai; MSD; Novartis; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck